Costimulation blockade in autoimmunity and transplantation.

Area of Science:

• Immunology
• Pharmacology

Background:

• T-cell activation relies on costimulation receptor signaling.
• Abatacept (cytotoxic T lymphocyte-associated antigen 4-Ig) targets CD80/CD86, inhibiting T-cell costimulation and treating rheumatoid arthritis.
• Belatacept, derived from abatacept, exhibits higher avidity for CD86, offering enhanced immunosuppression for transplantation.

Purpose of the Study:

• To review preclinical and clinical findings of abatacept and belatacept.
• To compare the tailored applications of these costimulation inhibitors in autoimmune diseases and organ transplantation.

Main Methods:

• Review of preclinical studies.
• Summary of recent clinical findings.

Main Results:

• Both abatacept and belatacept effectively inhibit the CD28 costimulatory pathway.
• Abatacept is indicated for autoimmune diseases like rheumatoid arthritis.
• Belatacept demonstrates potent immunosuppression suitable for organ transplantation.

Conclusions:

• Abatacept and belatacept are selective costimulation inhibitors targeting the CD28 pathway.
• These molecules are optimized for distinct therapeutic areas: abatacept for autoimmune conditions and belatacept for transplantation.